34 results about "Bone morphogenetic protein" patented technology

Disclosed herein are methods for treating a disease or disorder of the central or peripheral nervous system by administering to a subject in thereof an agent capable of modulating the activity or expression of bone morphogenetic protein and activin membrane-bound inhibitor (BAMBI). Additionally, methods for screening agents capable of modulating the activity or expression of BAMBI are disclosed.

The present application belongs to the field of biomedicine, and relates to an inducer for inducing mesenchymal stem cells to differentiate into estradiol-secreting cells. The inducer for inducing mesenchymal stem cells to differentiate into estradiol-secreting cells is based on a human mesenchymal stem cell serum-free culture medium, and is composed of the following components in a mass concentration ratio: bone morphogenetic protein-4 20-60 mg / L, bone morphogenetic protein-7 20-60 mg / L, tretinoin 2-8 mg / L, resveratrol 2-8 mg / L, icariin 2-8 mg / L, benzamide 2-8 ug / L, chloroplatinic acid hexahydrate 2-8 ug / L, ethanolamine 2-8 ug / L, erythropoietin 2-10 ug / L, and vascular endothelial growth factor 2-10 ug / L. The inducer for inducing mesenchymal stem cells to differentiate into estradiol-secreting cells has high induction efficiency.

The present invention provides a method for producing neural crest cells from pluripotent stem cells, the method comprising: a step (1) of subjecting pluripotent stem cells to suspension culture in a culture medium containing an ALK inhibitor and a bone morphogenetic protein; and (2) performing suspension culture in a culture medium containing an ALK inhibitor and a GSK-3beta inhibitor.

The application provides a bone morphogenetic protein BMP-2 recombinant protein, and the amino acid sequence of the BMP-2 recombinant protein is shown as SEQ ID No. 1. The coding gene, the expression plasmid, the prokaryotic expression vector and the prokaryotic expression method are also disclosed. The prokaryotic expression system is adopted, and a solubilization tag is creatively introduced, so that the inclusion body expression is converted into soluble expression. The BMP-2 is expressed in the form of inclusion body in the prokaryotic system, the protein is converted into soluble expression by adding the solubilization tag, the difficulty of protein separation and purification is reduced, the purification cycle is shortened, and the purification efficiency is improved.

The invention provides a bone repair material and a preparation method and application thereof, the bone repair material is composed of BMP protein (bone morphogenetic protein), carboxymethyl chitosan and calcium chloride, the carboxymethyl chitosan is crosslinked through calcium chloride to form nanoparticles, and the BMP protein is effectively loaded through electrostatic interaction; the bone repair material has good biocompatibility, biosafety and biodegradability, not only can effectively wrap and protect BMP protein from rapid degradation by enzyme, enhance in-vivo stability of BMP protein and realize continuous and controllable release of BMP protein, but also is beneficial to reduction of oedema and ectopic bone risks due to low-dose medication, and has good application prospects. And finally, by promoting angiogenesis, promoting bone tissue development and relieving inflammation, formation and repair of bones are achieved.

The application relates to the technical field of orthopedic repair material preparation, and discloses a sterile preparation and injection device for autologous red blood cell drug-loaded blood gel, which comprises a cross bolt mixer, a multimodal injector combined with a composite syringe and a mixing flow channel, the cross bolt is internally integrated with a microfluidic mixing channel, a vertical shaft direction and a coronal shaft direction are respectively connected with a main injector and a drug-loaded injector, when the red blood cell-rich plasma enters the bolt, longitudinal shear force is generated through a spiral flow channel, so that bone morphogenetic protein suspension is vertically injected into a main flow channel through a one-way valve structure, equal ratio mixing of 4:1 is realized in the spiral channel, and the whole mixing process is completed in a closed system. The device has the advantages of realizing accurate and uniform mixing of the red blood cell-rich plasma and the drug in a sterile environment, reducing the risk of bacterial contamination, being capable of directly injecting and filling bone defects for the prepared blood gel, being excellent in biological safety and compatibility, and being low in preparation cost and simple in process.

The invention provides a method of producing a population of CD34+ hematopoietic precursor cells. The CD34+ hematopoietic precursor cells are used in methods of producing natural killer (NK), methods of inducing NK cell differentiation from pluripotent stem cells (PSCs), and methods of generating terminally differentiated hematopoietic cells from PSCs. The differentiation of immune cells such as NK cells from PSCs includes the use of a hemogenic endothelium induction cocktail that includes a WNT signaling pathway activator, a bone morphogenetic protein and / or a vascular endothelial growth factor. Also provided is a method of producing hematopoietic stem cells from pluripotent stem cells.

This invention discloses a composition for the differentiation of mesenchymal stem cells (ADSCs) into keratinocytes and its application. The composition comprises: a Wnt signaling pathway activator, a TGF-β signaling pathway inhibitor, a bone morphogenetic protein pathway activator, and at least one of retinoic acid and a retinoic acid agonist. The small molecule composition provided by this invention is meticulously designed to gradually guide the fate transition of ADSCs by mimicking key signaling events during embryonic development. This strategy is not a simple compound screening, but a rational design based on a deep understanding of developmental biology, achieving precise regulation of cell lineages in vitro by reproducing the natural developmental process. The composition of this invention is not a simple superposition of components, but rather achieves cell fate transition by precisely regulating the balance of signaling pathway networks.

This invention discloses a reductase mutant and its application in the preparation of S-Bosein. The reductase mutant differs from the amino acid sequence shown in SEQ ID NO:3 in containing one or more amino acid residues at sites Q95, L96, and G190. The reductase mutant of this invention exhibits high substrate conversion and high ee value of S-Bosein when using β-pyruvate as a substrate, making it suitable for industrial production.

The application provides a bone nodule organoid and a preparation method and application thereof, the bone nodule organoid comprises a microsphere carrier system, the microsphere carrier system is made of CGRP, BMP-2, bone marrow mesenchymal stem cells and GelMA-HA-NB hydrogel by a light curing 3D printing technology, the microsphere carrier system is mixed with GelMA hydrogel containing SP to be crosslinked and solidified to form the bone nodule organoid, and the bone nodule organoid is used for in-vivo transplantation to stimulate endogenous bone tissue rapid regeneration;The bone nodule organoid has the ability of two-phase delivery of bioactive factors, different bioactive factors can realize time sequence, differential low dose, slow and continuous release, so that the healing speed and bone repair effect of large-size bone defect are accelerated in a divide-and-rule manner.The application also provides a bioactive factor composition of a bionic bone nodule tissue neurotrophic factor and a physiological dose of bone morphogenetic protein, the composition releases the bone marrow mesenchymal stem cell osteogenic differentiation in the bone nodule organoid according to signal time sequence.

The present application relates generally to the field of bone morphogenetic protein (BMP) antagonists (soluble ALK6 fusion proteins), compositions thereof, and methods for treating degenerative and / or demyelinating diseases of the nervous system.

The present disclosure aims to provide a nanofiber membrane for bone regeneration manufactured by electrospinning a polymer solution containing a polyethylene oxide and bone morphogenetic protein. The nanofiber membrane, according to the present disclosure, may be applied to an area of a bone defect by means of electrospinning to promote bone regeneration.

1. Name of the designed product: packing bottle (SGF bone-derived factor gel candy). 2. Use of the designed product: used for filling health and nutrition diet products. 3. Design points of the designed product: in shape. 4. Picture or photo best indicating the design points: perspective view.

To provide a defined culture medium for isolating stratified epithelial stem cells and stably maintaining the epigenetics of the stratified epithelial stem cells during multiple passages, and to provide clonal stratified epithelial stem cells isolated using the defined culture medium.SOLUTION: And a defined culture medium comprising each of ROCK (Rho kinase) inhibitors, mitogenic growth factors, insulin or IGF, TrkA inhibitors, and Oct4 activators, and comprising at least one of VEGF inhibitors, tyrosine kinase inhibitors, and / or FGF10 or FGF10 agonists, and optionally further comprising TGF β signaling pathway inhibitors and / or bone morphogenetic proteins (BMP) antagonists, wherein the defined culture medium supports epigenetically stable growth and proliferation of stem cells of stratified epithelial tissue origin in culture.SELECTED DRAWING: Figure 1

The application discloses a bone cement material, a preparation method and application thereof. The bone cement material is prepared from a bone cement raw material which is composed of polyethylene glycol (PEG) and calcium phosphate (CPC) and doped with bone morphogenetic protein-2 (BMP-2) under the action of a crosslinking agent. The bone cement material has the properties of slow and stable release, high osteogenic activity and the like under the condition of adding a small amount of BMP-2.

The invention belongs to the technical field of nano drug delivery systems, and particularly relates to a bone morphogenetic protein loaded nano drug delivery system and application in postoperative healing, and the bone morphogenetic protein loaded nano drug delivery system comprises a composite carrier, a targeted modification layer and loaded bone morphogenetic protein; the composite carrier is formed by compounding an inorganic nano material and a biodegradable polymer, the targeted modification layer is a bone injury part specific recognition molecule, and the nano drug-loading system has an intelligent release mechanism responding to a bone healing microenvironment and can be applied to orthopedic postoperative healing.

The application provides a composite fiber scaffold for treating osteoarthritis and promoting tendon-bone healing and a preparation method thereof, and belongs to the technical field of biological medicine. The composite fiber scaffold of the application is a core-shell structure, the shell layer is based on PLGA, and is loaded with platelet exosomes (PLT-Exos) and curcumin; the core is based on gelatin hydrogel, and is loaded with bone morphogenetic protein-2 (BMP-2) and icariin. The scaffold can realize time-controlled release of drugs by coaxial electrospinning technology: the shell layer drug is rapidly released to resist inflammation and regulate the immune microenvironment, and the core drug is slowly released to long-acting promote tendon-bone regeneration. The application is particularly suitable for treating osteoarthritis caused by dislocation of the distal ulno-radiate joint, and can significantly improve the tendon-bone healing quality after ligament reconstruction, and has the advantages of synergistic effect and good biocompatibility.

A bone graft material includes a shielding film configured to cover an upper surface of a bone defect and separate the bone defect from an external environment and impregnated with a bone morphogenetic protein-2 (BMP-2) solution, and a filler that contacts a lower surface of the shielding film and is configured to fill the bone defect. The bone graft material is designed such that, by impregnating the BMP-2 solution into the shield film so as to form a bone cover of the bone defect, and the filler at the bottom of the shield film can sufficiently form bone in the cover.

The application discloses a plastic bone repair composite scaffold loaded with bone morphogenetic protein-2 and a preparation method thereof, and belongs to the technical field of biological repair materials. The preparation method comprises the following steps: mixing biological ceramic powder, modified starch and deionized water to obtain ceramic slurry through wet grinding, printing the ceramic slurry to obtain a biological ceramic scaffold blank, crushing the biological ceramic scaffold blank after sintering treatment to obtain biological ceramic particles; mixing the biological ceramic particles and a collagen fiber slurry, defoaming and then freeze-drying to obtain a ceramic collagen composite scaffold; placing the ceramic collagen composite scaffold into a crosslinking mixed solution for crosslinking, and then sequentially performing water washing, freeze-drying and sterilization to obtain a bone repair porous scaffold; and adding a CBD-rhBMP-2 solution dropwise to the bone repair porous scaffold to obtain the bone repair composite scaffold. The bone repair composite scaffold prepared by the method has good plastic stability and compressive strength, and has good osteogenic activity, and has practical use value.

1. Name of the product in this design: Packaging Bottle (SGF Bone Factor). 2. Purpose of this design: For use as a filling for healthy and nutritious dietary products. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: a 3D model.

A membrane for guided bone regeneration includes a hydrogel containing alginate and gelatin at a weight ratio of 1:1.0-1.6, and impregnated with a bone morphogenetic protein (BMP). With this method, the membrane can be conveniently administered by syringe injection, and the manufacturing process is simple, requires no complex equipment, and is advantageous in terms of time and cost, while providing improved therapeutic effects.

This invention provides a mesenchymal stem cell culture medium, its preparation method, and its application. The mesenchymal stem cell culture medium of this invention includes a basal culture medium and functional additives. The functional additives include: recombinant human albumin, recombinant transferrin, recombinant bone morphogenetic protein; recombinant insulin or insulin-like growth factor, recombinant fibroblast growth factor, recombinant epidermal growth factor, recombinant platelet-derived growth factor; thyroid hormones, ethanolamine, carnitine, glucocorticoid regulators, retinoic acid compounds; heparin sodium, signal-regulating lipids, cholesterol, DL-α-tocopherol acetate, linolenic acid, oleic acid, stearic acid; prolactin F68, and Tween 80. The mesenchymal stem cell culture medium of this invention does not contain immunogenic proteins or blood products derived from animals or humans. All components can be supplied with GMP-compliant raw materials and the process can be controlled, ensuring the controllability, safety, and reproducibility of the culture process.

A method of producing a mesodermal-lineage primitive streak cell includes a first step of culturing pluripotent stem cells in a medium containing FGF2, BMP (bone morphogenetic protein) 4, a GSK-3β inhibitor, and retinoic acid or a derivative thereof and a second step of culturing cells obtained in the first step in a medium containing FGF2, a GSK-3β inhibitor, and BMP7.

The application relates to the field of biotechnology, and discloses a culture medium system for maintaining and directionally inducing pluripotency of embryonic stem cells and application thereof. The culture medium comprises the following components in mass fractions: human insulin: 8-12 parts; tetramethylene diamine: 0.5-0.8 parts; luteinizing hormone: 0.2-0.5 parts; vitamin mixture: 1-2 parts; bovine serum albumin: 2-4 parts; sodium bicarbonate: 0.5-1.0 parts; antibiotic mixture: 0.2-0.4 parts; biotin: 1-2 parts; bone morphogenetic protein: 0.5-1.0 parts; and magnesium ethylenediaminetetraacetate: 0.1-0.2 parts. The application constructs a multi-factor regulation system, combines a signal inhibition, a three-dimensional support and a metabolic regulation module, realizes stable maintenance of pluripotency of embryonic stem cells, significantly improves culture uniformity, structural support and anti-differentiation capacity, and breaks through the technical bottleneck of a traditional system in terms of induction efficiency and stability.

This invention discloses a bioactive suture for muscle fixation surgery and its preparation method. The suture has a coaxial three-layer structure, comprising a shape memory polymer core layer, a biodegradable intermediate layer, and a permanently woven outer shell layer radially from the inside to the outside, and longitudinally divided into three functional zones: a bone end zone, a transition zone, and a tendon end zone. The shape memory polymer core layer uses a polylactic acid / polyhydroxybutyrate valerate blend, which triggers controlled contraction under body temperature and hydration conditions, automatically compensating for tension loss caused by postoperative edema reduction. The biodegradable intermediate layer uses polylactic acid-glycolic acid copolymer microspheres with different ratios to achieve longitudinal, zoned, and time-sequential release of various bioactive factors such as bone morphogenetic protein-2 and vascular endothelial growth factor. This invention integrates tension self-regulation, time-sequential release, and surface biomimicry, and is suitable for tendon-bone insertion reconstruction after amputation.

The present disclosure belongs to the field of biological medicines, and relates to an inducer for inducing differentiation of mesenchymal stem cells into estradiol-secreting cells. The inducer for inducing differentiation of mesenchymal stem cells into estradiol-secreting cells uses human mesenchymal stem cell serum-free culture medium as a substrate and comprises the following components in mass concentration ratios: 20-60 mg / L of bone morphogenetic protein-4, 20-60 mg / L of bone morphogenetic protein-7, 2-8 mg / L of retinoic acid, 2-8 mg / L of resveratrol, 2-8 mg / L of icariin, 2-8 μg / L of benzamide, 2-8 μg / L of chloroplatinic acid hexahydrate, 2-8 μg / L of ethanolamine, 2-10 μg / L of erythropoietin and 2-10 μg / L of vascular endothelial growth factor. The inducer for inducing differentiation of mesenchymal stem cells into estradiol-secreting cells provided by the present disclosure has a high induction efficiency.

A method for producing a composite demineralized bone matrix composition using a one-step process is described. The composite demineralized bone matrix composition is produced from the biologically-derived bone. In addition, the composite demineralized bone matrix composition contains bone minerals according to the original composition proportion in the bone and may provide a bone mineral content condition that is closest to that in an environment in which in vivo bone formation occurs. In addition, the composition contains a bone morphogenetic protein (BMP-2), and thus enables a stable and excellent bone formation effect to be derived.

The present invention relates to uses of a combination therapy of bone morphogenetic protein-2 and denosumab in spinal fusion surgery. When bone morphogenetic protein-2 and denosumab are used in combination during spinal fusion surgery as in the present invention, side effects frequently occurring due to spinal fusion surgery, such as osteolysis, inflammation, wound dehiscence, and bleeding, can be effectively prevented and treated.

Provided is a method of controlling local release of target compounds by patterning a hydrogel carrying a bone morphogenetic protein or anticancer drug as the target compounds onto an electrospun nanoporous membrane. The hydrogel is capable of controlling local release of the bone morphogenetic protein or anticancer drug as a carrier of the bone morphogenetic protein or anticancer. And the electrospun nanoporous membrane performs a basic function of the membrane of preventing infiltration of connective tissue. Thus, there is an advantage in that the hydrogel patterned nanoporous membrane can facilitate generation of controlled bone in a local region and degradation of cancer in a local region.